Mabpharm (HKSE:02181) Change In Receivables : HK$-11.23 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Change In Receivables?

Mabpharm's change in receivables for the quarter that ended in Dec. 2023 was HK$17.22 Mil. It means Mabpharm's Accounts Receivable declined by HK$17.22 Mil from Jun. 2023 to Dec. 2023 .

Mabpharm's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-11.23 Mil. It means Mabpharm's Accounts Receivable increased by HK$11.23 Mil from Dec. 2022 to Dec. 2023 .

Mabpharm's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$21.24 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Mabpharm's Days Sales Outstanding for the six months ended in Dec. 2023 was 82.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mabpharm's liquidation value for the six months ended in Dec. 2023 was HK$-646.41 Mil.

Mabpharm Change In Receivables Historical Data

The historical data trend for Mabpharm's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Change In Receivables Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.28

-4.18

-2.49

0.17

-11.23

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial								-7.94	7.16	-6.65	-28.45	17.22

Mabpharm Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-11.23 Mil.

Mabpharm (HKSE:02181) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Mabpharm's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	21.244	/	47.187	*	91
=	82.16

2. In Ben Graham's calculation of liquidation value, Mabpharm's accounts receivable are only considered to be worth 75% of book value:

Mabpharm's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	189.601	-	907.745	+	0.75 * 21.244	+	0.5 * 111.606
=	-646.41

Mabpharm Change In Receivables Related Terms

Thank you for viewing the detailed overview of Mabpharm's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines